Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial
Authors:
- 1 June 2020
- journal article
- research article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 5 (6) , 548-560
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81521091)
This publication has 26 references indexed in Scilit:
- Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinomaNuclear Medicine Communications, 2013
- 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinomaWorld Journal of Gastroenterology, 2013
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-upJournal of Nuclear Medicine, 2008
- Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinomaEuropean Journal Of Cancer Prevention, 2007
- HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular CarcinomaMolecular Cancer Research, 2007
- A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantationHepatology, 2007
- Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Early and Late Recurrence After Liver Resection for Hepatocellular CarcinomaAnnals of Surgery, 2006
- Hematogenous Spreading of Hepatocellular Carcinoma Cells: Possible Participation in Recurrence in the LiverHepatology, 1997